• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Apple, Eli Lilly Research Whether Devices Can Detect Dementia Signs

Share:

August 14, 2019

Dive Brief:

  • Apple and pharmaceutical giant Eli Lilly are conducting joint research to see whether health features on the iPhone and Apple Watch can detect evidence of dementia and cognitive decline. The two companies, along with health tech startup Evidation, found promising initial results but concluded additional research is needed.
  • The early-stage, 12-week study included 31 people with various stages of cognitive impairment and an 82-person healthy control group. Researchers collected 1.5 gigabytes of data per participant per day, including data on motor function and sleep rhythms.
  • People with symptoms of cognitive decline showed slower typing, less regularity in schedules, fewer text messages and greater reliance on helper apps such as the Clock app than their healthy counterparts.

Dive Insight:

The partnership between the tech giant and the pharmaceutical company, although tenuous, illustrates how boundaries continue to blur between the traditional healthcare industry and outside players.

Dementia, which affects roughly 47 million people across the globe, costs $1 trillion worldwide, according to the World Health Organization. Early testing for the condition is sporadic and, when conducted, it’s often not sensitive enough to detect early stages of mental decline, creating an opportunity for tech companies like Apple to see whether they can turn a profit.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The “rich, longitudinal information” from wearable and mobile consumer devices can be “mined for physiological and behavioral signatures of cognitive impairment and provide new avenues for detecting [mild cognitive impairment] in a timely and cost-effective manner,” researchers wrote in the paper. The team included five authors from Apple, five from Eli Lilly and five from Evidation.

Data was collected from a slew of platforms including an iPhone, Apple Watch, iPad and a Beddit sleep monitoring device, then stored on a HIPAA-compliant Evidation platform. Researchers had access to the data through a secure network called a VPN before modeling. Apple bought sleep tracking company Beddit in May 2017.

The initial results are promising, but researchers stressed they’re only a “starting point” for further studies on using the consumer gadgets to predict cognitive decline, which includes Alzheimer’s disease.

The Apple Watch already has a slew of health features, including menstrual cycle tracking and heart rate and EKG monitoring. Although the company stresses the wellness and preventive care benefits of the tech, early results are mixed.

It’s’s unclear whether wearables like the Apple Watch or popular fitness tracker Fitbit really improve the health of their owners, but a number of payers are offering the tech to their beneficiaries. The list includes CVS-owned Aetna and potentially a number of privately-owned Medicare Advantage plans.

Additionally, as the site of care moves increasingly to the home, sensors that predict falls, monitor voice quality for sickness, and (potentially) screen for dementia could be lucrative for manufacturers and other healthcare players.

Date: August 14, 2019

Source: Healthcare Dive

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Aiberry Secures $8M for AI-Powered Mental Health ScreeningsAiberry Secures $8M for AI-Powered Mental Health Screenings
  • Icario Acquires Consumer Engagement and Health Action Platform ChipRewardsIcario Acquires Consumer Engagement and Health Action Platform ChipRewards
  • 2020 Medical Devices Pipeline Assessment for Aesthetic Devices2020 Medical Devices Pipeline Assessment for Aesthetic Devices
  • Pattern Health Scores $3.3M for No-Code Digital Health Creation PlatformPattern Health Scores $3.3M for No-Code Digital Health Creation Platform
  • Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of CelgeneBristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
  • AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience PipelineAbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
  • Putting Data And Analytics Tools In The Hands Of A Broader AudiencePutting Data And Analytics Tools In The Hands Of A Broader Audience
  • What If AI Could Uber The Healthcare Industry?What If AI Could Uber The Healthcare Industry?

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications